Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by SQZ Biotechnologies

SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange

January 18, 2023

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer

November 30, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting

November 10, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates

November 09, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates

August 04, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer

July 11, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies to Present at Jefferies Healthcare Conference

June 01, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer

May 31, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process

May 18, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates

May 10, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022

May 05, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research

May 05, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies to Present at Upcoming Investor Conferences

May 03, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

April 27, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo

April 11, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies to Present at Upcoming Investor Conferences

April 06, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

April 04, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson’s Disease

March 21, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Reports Full Year 2021 Financial Results and Recent Portfolio Updates

March 16, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC’s Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation

February 01, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors

January 24, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Announces Healthcare Industry Leader John Maraganore, Ph.D. Joining as Strategic Advisor

January 06, 2022

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies to Present at the 4th Annual Evercore ISI HealthCONx Conference

November 29, 2021

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Presents New AAC, eAPC Platform Research and First Enhanced Tumor Infiltrating Lymphocyte Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting

November 12, 2021

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Announces Independent DSMB Recommendation to Advance Lead Cell Therapy Candidate Into Combination With Checkpoint Inhibitors

October 26, 2021

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting

October 04, 2021

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies to Present at the Chardan 5th Annual Genetic Medicines Conference

September 30, 2021

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies to Present at Cantor Global Healthcare Conference

September 27, 2021

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform

September 13, 2021

From SQZ Biotechnologies

Via Business Wire

SQZ Biotechnologies to Present at Upcoming Health Care Conferences

September 09, 2021

From SQZ Biotechnologies

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by SQZ Biotechnologies

Starting at $3.75/week.

Subscribe Today